Literature DB >> 12936977

Antimicrobial characterization of human beta-defensin 3 derivatives.

David M Hoover1, Zhibin Wu, Kenneth Tucker, Wuyuan Lu, Jacek Lubkowski.   

Abstract

Human beta-defensin 3 (hBD3) is a highly basic 45-amino-acid protein that acts both as an antimicrobial agent and as a chemoattractant molecule. Although the nature of its antimicrobial activity is largely electrostatic, the importance of the molecular structure on this activity is poorly understood. Two isoforms of hBD3 were synthesized: the first with native disulfide linkages and the second with nonnative linkages. In a third synthetic peptide, all cysteine residues were replaced with alpha-aminobutyric acid, creating a completely linear peptide. A series of six small, linear peptides corresponding to regions of hBD3 with net charges ranging from +4 to +8 (at pH 7) and lengths ranging from 9 to 20 amino acids were also synthesized. The linear full-length peptide showed the highest microbicidal activity against Escherichia coli and Staphylococcus aureus, while all three full-length forms showed equal activity against Candida albicans. The linear peptide also showed high activity against Enterococcus faecium and Pseudomonas aeruginosa. Peptides corresponding to the C terminus showed higher activities when tested against E. coli, with the most active peptides being the most basic. However, only the peptide corresponding to the N terminus of hBD3 showed any activity against S. aureus and C. albicans. Further, N-terminal deletion mutants of native hBD3 showed diminished activities against S. aureus. Thus, the antimicrobial properties of hBD3 derivatives are determined by both charge and structure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12936977      PMCID: PMC182640          DOI: 10.1128/AAC.47.9.2804-2809.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins.

Authors:  Y Q Tang; J Yuan; G Osapay; K Osapay; D Tran; C J Miller; A J Ouellette; M E Selsted
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

2.  Cryptdin-3 induces novel apical conductance(s) in Cl- secretory, including cystic fibrosis, epithelia.

Authors:  D Merlin; G Yue; W I Lencer; M E Selsted; J L Madara
Journal:  Am J Physiol Cell Physiol       Date:  2001-02       Impact factor: 4.249

Review 3.  Current status of defensins and their role in innate and adaptive immunity.

Authors:  Periathamby Antony Raj; Andrew R Dentino
Journal:  FEMS Microbiol Lett       Date:  2002-01-02       Impact factor: 2.742

4.  Antibacterial activities and conformations of bovine beta-defensin BNBD-12 and analogs:structural and disulfide bridge requirements for activity.

Authors:  M Mandal; M V Jagannadham; R Nagaraj
Journal:  Peptides       Date:  2002-03       Impact factor: 3.750

5.  Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity.

Authors:  J R García; A Krause; S Schulz; F J Rodríguez-Jiménez; E Klüver; K Adermann; U Forssmann; A Frimpong-Boateng; R Bals; W G Forssmann
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

6.  The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus.

Authors:  David J Schibli; Howard N Hunter; Vladimir Aseyev; Timothy D Starner; John M Wiencek; Paul B McCray; Brian F Tack; Hans J Vogel
Journal:  J Biol Chem       Date:  2001-12-11       Impact factor: 5.157

7.  DNA as the intracellular secondary target for antibacterial action of human neutrophil peptide-I against Mycobacterium tuberculosis H37Ra.

Authors:  S Sharma; G Khuller
Journal:  Curr Microbiol       Date:  2001-07       Impact factor: 2.188

8.  Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction.

Authors:  J R García; F Jaumann; S Schulz; A Krause; J Rodríguez-Jiménez; U Forssmann; K Adermann; E Klüver; C Vogelmeier; D Becker; R Hedrich; W G Forssmann; R Bals
Journal:  Cell Tissue Res       Date:  2001-11       Impact factor: 5.249

9.  Susceptibility of nontypeable Haemophilus influenzae to human beta-defensins is influenced by lipooligosaccharide acylation.

Authors:  Timothy D Starner; W Edward Swords; Michael A Apicella; Paul B McCray
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Treponema denticola is resistant to human beta-defensins.

Authors:  Catherine A Brissette; Sheila A Lukehart
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

View more
  82 in total

Review 1.  Human genetic susceptibility to Candida infections.

Authors:  Theo S Plantinga; Melissa D Johnson; William K Scott; Leo A B Joosten; Jos W M van der Meer; John R Perfect; Bart Jan Kullberg; Mihai G Netea
Journal:  Med Mycol       Date:  2012-06-04       Impact factor: 4.076

2.  Toll-like receptor 1 polymorphisms increase susceptibility to candidemia.

Authors:  Theo S Plantinga; Melissa D Johnson; William K Scott; Esther van de Vosse; Digna R Velez Edwards; P Brian Smith; Barbara D Alexander; John C Yang; Dennis Kremer; Gregory M Laird; Marije Oosting; Leo A B Joosten; Jos W M van der Meer; Jaap T van Dissel; Thomas J Walsh; John R Perfect; Bart Jan Kullberg; Mihai G Netea
Journal:  J Infect Dis       Date:  2012-02-01       Impact factor: 5.226

3.  Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules.

Authors:  Sascha Jung; Justyna Mysliwy; Björn Spudy; Inken Lorenzen; Karina Reiss; Christoph Gelhaus; Rainer Podschun; Matthias Leippe; Joachim Grötzinger
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

4.  Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3.

Authors:  Viswanatha Krishnakumari; Nandini Rangaraj; Ramakrishnan Nagaraj
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

5.  Effects of cations and pH on antimicrobial activity of thanatin and s-thanatin against Escherichia coli ATCC25922 and B. subtilis ATCC 21332.

Authors:  Guoqiu Wu; Jiaxuan Ding; Hui Li; Linxian Li; Rui Zhao; Zilong Shen; Xiaobo Fan; Tao Xi
Journal:  Curr Microbiol       Date:  2008-09-23       Impact factor: 2.188

6.  Highly active and selective endopeptidases with programmed substrate specificities.

Authors:  Navin Varadarajan; Sarah Rodriguez; Bum-Yeol Hwang; George Georgiou; Brent L Iverson
Journal:  Nat Chem Biol       Date:  2008-05       Impact factor: 15.040

7.  Immunology: Peptide gets in shape for self-defence.

Authors:  Robert I Lehrer
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

8.  The synthetic form of a novel chicken beta-defensin identified in silico is predominantly active against intestinal pathogens.

Authors:  Rowan Higgs; David J Lynn; Susan Gaines; Jessica McMahon; Joanna Tierney; Tharappel James; Andrew T Lloyd; Grace Mulcahy; Cliona O'Farrelly
Journal:  Immunogenetics       Date:  2005-03-03       Impact factor: 2.846

9.  Human beta-defensins kill Candida albicans in an energy-dependent and salt-sensitive manner without causing membrane disruption.

Authors:  Slavena Vylkova; Namrata Nayyar; Wansheng Li; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  The antimicrobial activity of CCL28 is dependent on C-terminal positively-charged amino acids.

Authors:  Bin Liu; Eric Wilson
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.